Janney Capital analyst Ken Trbovich upgraded BioDelivery Sciences (BDSI) to Buy from Neutral, stating that Endo International (ENDP) has "not yet announced, but clearly won" preferred status for Belbuca relative to market leader Butrans on United Healthcare's Prescription Drug List. Endo's Belbuca utilizes BioDelivery Sciences' patented BioErodible MucoAdhesive drug delivery technology. The United contract, paired with the fact that BioDelivery has announced five contract wins for Bunavail since July, put Bunavail on a path to show meaningful growth in 2017, said Trbovich, who maintains his $4 fair value estimate on the stock.